medigraphic.com
ISSN 2594-1518 (Electronic)
ISSN 1405-0099 (Print)

2018, Number 1

<< Back Next >>

Cir Gen 2018; 40 (1)

Ten-year review of malignant mammary pathology in males; Hospital General Universitario, Ciudad Real (Spain)

Alberca PA, Sánchez FJA, Picón RR, Villsanti Rn, Pardo GR, Gil RA, Fernández JM

Language: Spanish
References: 27
Page: 8-12
PDF size: 188.12 Kb.


ABSTRACT

Introduction: Male breast cancer (MBC) is a rare condition usually diagnosed later and in more advanced stages than female breast cancer. Methods: A 10-year retrospective review of MBC in our hospital. Results: Our series included 13 cases. We analyzed the form of presentation, way of diagnosis, BRCA mutation, histology of the tumor, the type of treatment and survival. Discussion: The incidence of MBC is currently increasing. The average age of presentation is 62 years. They usually consult because of a nodule or painless retroareolar tumor. Lymph node involvement is often diagnosed. Diagnosis is usually late, which contributes to the infiltration of the pectoralis major muscle. There is no screening in males. Surgical treatment consists of the removal of the primary tumor. The axillary treatment is based on the selective biopsy of the sentinel ganglion (BSGC) for its staging. The use of radio, chemo and endocrine therapy is usually advised depending on the axillary and distance staging, and the type of hormonal receptors of the tumor. Overall and disease-free survival in males are below the ones in the female population. Conclusion: Most of the conclusions of this pathology in the male derive from studies of female breast cancer.


REFERENCES

  1. Borrego-Galán M, Oltra A, Espinoza S, Munárriz B, Sancho-Fornos S, Herranz C. Cáncer de mama en el varón: revisión de 27 casos. Rev Senol Patol Mamar. 1998; 11: 187-190.

  2. Vilhelm MC, Wanebo HJ. Cáncer de mama en el hombre. En: Manejo multidisciplinario de las enfermedades benignas y malignas. Panamericana; 1993. Capítulo 5: 83-95.

  3. Aguilar-Luque J, Sarmiento-Robles C, Merino de la Torre E, Martínez-García P. Carcinoma de mama en el varón: análisis de 5 casos y revisión bibliográfica. Rev Cubana Cir. 2001; 40: 66-72.

  4. White J, Kearins O, Dodwell D, Horgan K, Hanby AM, Speirs V. Male breast carcinoma: increased awareness needed. Breast Cancer Res. 2011; 13: 219.

  5. Golshan M, Rusby J, Dominguez F, Smith BL. Breast conservation for male breast carcinoma. Breast. 2007; 16: 653-656.

  6. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: a population-based study. Cancer. 2004; 101: 51-57.

  7. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-249.

  8. Alonso A, Aguilar F, Santos JA. Carcinoma de mama en el varón: revisión de 32 casos. Oncología. 1983; 16: 29-35.

  9. Joshi MG, Lee AK, Loda M, Camus MG, Pedersen C, Heatley GJ, et al. Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer. 1996; 77: 490-498.

  10. Deb S, Lakhani SR, Ottini L, Fox SB. The cancer genetics and pathology of male breast cancer. Histopathology. 2016; 68: 110-118.

  11. Deb S, Jene N; Kconfab Investigators, Fox SB. Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas. BMC Cancer. 2012; 12: 510.

  12. Ferzoco RM, Ruddy KJ. Optimal delivery of male breast cancer follow-up care: improving outcomes. Breast Cancer (Dove Med Press). 2015; 7: 371-379.

  13. Onami S, Ozaki M, Mortimer JE, Pal SK. Male breast cancer: an update in diagnosis, treatment and molecular profiling. Maturitas. 2010; 65(4): 308-314.

  14. Lyman GH, Giuliano AE, Somerfield MR, Benson AB 3rd, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005; 23: 7703-7720.

  15. Gentilini O, Chagas E, Zurrida S, Intra M, De Cicco C, Gatti G, et al. Sentinel lymph node biopsy in male patients with early breast cancer. Oncologist. 2007; 12: 512-515.

  16. Contractor KB, Kaur K, Rodrigues GS, Kulkarni DM, Singhal H. Male breast cancer: is the scenario changing. World J Surg Oncol. 2008; 6: 58.

  17. Yoney A, Kucuk A, Unsal M. Male breast cancer: a retrospective analysis. Cancer Radiother. 2009; 13: 103-107.

  18. Patel HZ 2nd, Buzdar AU, Hortobagyi GN. Role of adjuvant chemotherapy in male breast cancer. Cancer. 1989; 64: 1583-1585.

  19. Spence RA, MacKenzie G, Anderson JR, Lyons AR, Bell M. Long-term survival following cancer of the male breast in Northern Ireland. A report of 81 cases. Cancer. 1985; 55: 648-652.

  20. Giordano SH. A review of the diagnosis and management of male breast cancer. Oncologist. 2005; 10: 471-479.

  21. Farrow JH, Adair FE. Effect of orchidectomy on skeletal metastases from cancer of the male breast. Science. 1942; 95: 654.

  22. Kantarjian H, Yap HY, Hortobagyi G, Buzdar A, Blumenschein G. Hormonal therapy for metastatic male breast cancer. Arch Intern Med. 1983; 143: 237-240.

  23. Meguerditchian AN, Falardeau M, Martin G. Male breast carcinoma. Can J Surg. 2002; 45: 296-302.

  24. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010; 28: 3784-3796.

  25. Giordano SH, Valero V, Buzdar AU, Hortobagyi GN. Efficacy of anastrozole in male breast cancer. Am J Clin Oncol. 2002; 25: 235-237.

  26. Giordano SH, Hortobagyi GN. Leuprolide acetate plus aromatase inhibition for male breast cancer. J Clin Oncol. 2006; 24: e42-e43.

  27. Yu E, Stitt L, Vujovic O, Joseph K, Assouline A, Younus J, et al. Male breast cancer prognostic factors versus female counterparts with propensity scores and matched-pair analysis. Cureus. 2015; 7: e355.




2020     |     www.medigraphic.com